Navidea Biopharmaceuticals Inc (NAVB)

[umiak]

Sigh..saying 2.50 is it till Q is disagreeable in the extreme. There is at least a 50% chance you are wrong. Also applying value stock principles to a developmental/cutting edge radiopharmaceutical company is at a minimum unusual. The fact that they have revenue, with signs of product adoption, late stage trials and a catalyst rich future makes that argument somewhat suspect imo.

Agree completely about news and company has confirmed good stuff is coming our way.

Looks like we're going to be stuck around the $2.50 level until the Q3 CC, assuming it contains some market shaking good news.....this stock deserves better, but realistically we have very little revenue, so on any "normal" P/E or PEG ratio it's probably overvalued even at this price - need some really good H&N news plus more on the brain imaging agents.